Coherus Oncology announced it will report its first quarter 2026 financial results after market close on May 11, 2026. The company will hold a conference call and webcast at 5:00 p.m. Eastern Time to discuss the results and provide a business update. Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and ongoing clinical trials for other cancer treatments. Investors can access the webcast and replay via the company’s investor website.
STMicroelectronics announced a $1.5 billion issuance of new convertible senior bonds in two tranches, with maturities of 5 and 7 years, alongside the early repayment of $750 million of zero-coupon convertible bonds due in 2027. The new bonds offer fi...
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
